You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 12, 2025

ONCASPAR Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Recent Clinical Trials for ONCASPAR

Identify potential brand extensions & biosimilar entrants

SponsorPhase
City of Hope Medical CenterPhase 1
M.D. Anderson Cancer CenterPhase 1/Phase 2
Julio Barredo, MDPhase 1

See all ONCASPAR clinical trials

Recent Litigation for ONCASPAR

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
JAZZ PHARMACEUTICALS IRELAND LIMITED v. LUPIN LTD.2023-01-19
Ravgen, Inc. v. Quest Diagnostics Incorporated2021-11-17
TwinStrand Biosciences, Inc. v. Guardant Health, Inc.2021-08-03

See all ONCASPAR litigation

PTAB Litigation
PetitionerDate
Illumina, Inc. et al.2021-07-20
Laboratory Corporation of America Holdings et al.2021-05-28
Quest Diagnostics Incorporated2021-04-15

See all ONCASPAR litigation

Pharmacology for ONCASPAR
Established Pharmacologic ClassAsparagine-specific Enzyme
Chemical StructureAsparaginase
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ONCASPAR Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ONCASPAR Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ONCASPAR Derived from Patent Text Search

These patents were obtained by searching patent claims

Market Dynamics and Financial Trajectory for the Biologic Drug: Oncaspar

Introduction to Oncaspar

Oncaspar, also known as pegaspargase, is a biologic drug primarily used in the treatment of acute lymphoblastic leukemia (ALL), a type of cancer that affects the white blood cells. This drug has been gaining significant traction in the oncology market due to its efficacy and the growing demand for advanced cancer treatments.

Market Size and Growth

The Oncaspar market is experiencing robust growth, driven by several key factors. As of 2024, the global Oncaspar market was valued at approximately USD 136.67 million and is projected to reach USD 464.38 million by 2032, with a compound annual growth rate (CAGR) of 16.52% during the forecast period[1].

Drivers of Market Growth

Increasing Incidence of ALL

The rising incidence of acute lymphoblastic leukemia, particularly in pediatric patients, is a significant driver of the Oncaspar market. This increase in patient numbers has led to a higher adoption rate of Oncaspar in hospitals, where it is often used as part of combination chemotherapy regimens[1].

Advancements in Biotechnology

Advancements in biotechnology have resulted in the development of more stable formulations of Oncaspar, such as lyophilized and liquid forms. These formulations are easier to store and administer, making Oncaspar a preferred option in hospitals with varying levels of resources and infrastructure[1].

Favorable Regulatory Environment

A favorable regulatory environment has also contributed to the growth of the Oncaspar market. Several approvals and endorsements by leading health organizations have improved the drug’s market presence and made it more accessible to a larger patient population[1].

Market Dynamics

Supply and Demand

The supply and demand dynamics play a critical role in the Oncaspar market. The increasing incidence of ALL drives demand, while regulatory approvals and production capacity influence supply. The balance between these factors is crucial for the market's overall growth[1].

Competitive Landscape

The Oncaspar market is characterized by a competitive environment, with pharmaceutical companies investing heavily in research and development to create improved formulations and expand the drug’s therapeutic use. The introduction of biosimilars and generic alternatives also impacts the market, driving down prices and affecting market share[1].

Regional Outlook

The Oncaspar market is segmented into several key regions, including North America, Europe, Asia-Pacific, and the Middle East & Africa. North America and Europe are currently the leading markets due to their well-established healthcare infrastructure and high healthcare spending. However, the Asia-Pacific region is expected to show the highest growth rate due to increasing healthcare investments and rising incidences of leukemia[1].

Financial Performance of Key Players

Servier Group

Servier, the primary manufacturer of Oncaspar, has reported significant financial growth driven by the drug's performance. In the 2021/22 financial year, Oncaspar generated revenue of €290 million, up 2.8% compared to the previous year[2].

For the 2022-2023 financial year, Servier's consolidated revenue increased by 9.2% to €5.327 billion, with brand-name medicine revenue, including Oncaspar, growing by 9.4% to €4.041 billion. The group's EBITDA margin also improved to 19.1%, reflecting strong cost control and higher sales[5].

Future Outlook and Challenges

Long-term Market Impact

Despite immediate challenges such as regulatory hurdles and potential side effects, the Oncaspar market is expected to recover and grow steadily in the post-pandemic period. The resumption of clinical trials, efforts to strengthen supply chain resilience, and the adoption of telemedicine and digital health technologies are anticipated to drive this growth[1].

Expansion into Emerging Markets

The expansion into emerging markets, particularly in the Asia-Pacific region, presents a significant growth opportunity for Oncaspar. Improving healthcare infrastructure and growing cancer awareness in these regions are expected to increase the demand for advanced cancer therapies like Oncaspar[1].

Continuous Research and Development

Continuous research and development activities are crucial for the future growth of the Oncaspar market. These efforts aim to innovate and improve the safety and efficacy profiles of the drug, potentially leading to newer formulations and expanded therapeutic uses[1].

Key Financial Metrics

  • Market Size (2024): USD 136.67 million[1]
  • Projected Market Size (2032): USD 464.38 million[1]
  • CAGR (2024-2032): 16.52%[1]
  • Revenue (Servier, 2021/22): €290 million[2]
  • EBITDA Margin (Servier, 2022-2023): 19.1%[5]

Regional Market Share

  • United States: Largest market with about 67% market share[3]
  • Europe: Follows the U.S., accounting for about 32% market share[3]
  • Asia-Pacific: Expected to show the highest growth rate due to increasing healthcare investments and rising incidences of leukemia[1]

Types and Applications

  • Types: Lyophilized Oncaspar, Liquid Oncaspar[3]
  • Applications: Large hospitals, small & medium hospitals[3]

Conclusion

The Oncaspar market is poised for significant growth driven by the increasing incidence of ALL, advancements in biotechnology, and a favorable regulatory environment. Despite challenges such as regulatory hurdles and competition from generic alternatives, the market is expected to benefit from continuous research and development and expansion into emerging markets.

Key Takeaways

  • The Oncaspar market is projected to grow significantly, driven by the increasing incidence of ALL and advancements in biotechnology.
  • Servier, the primary manufacturer, has reported strong financial performance driven by Oncaspar sales.
  • The Asia-Pacific region is expected to show the highest growth rate due to increasing healthcare investments.
  • Continuous research and development are crucial for the future growth of the Oncaspar market.
  • The market faces challenges such as regulatory hurdles and competition from generic alternatives.

FAQs

Q: What is the projected market size of Oncaspar by 2032? A: The global Oncaspar market is projected to reach USD 464.38 million by 2032[1].

Q: What is the CAGR of the Oncaspar market from 2024 to 2032? A: The Oncaspar market is expected to exhibit a CAGR of 16.52% from 2024 to 2032[1].

Q: Which region has the largest market share for Oncaspar? A: The United States has the largest market share for Oncaspar, accounting for about 67% of the market[3].

Q: What are the main types of Oncaspar formulations? A: The main types of Oncaspar formulations are lyophilized and liquid forms[3].

Q: Who is the primary manufacturer of Oncaspar? A: Servier is the primary manufacturer of Oncaspar[2].

Sources

  1. Global Growth Insights: Oncaspar Market Size, Share, Analysis, Trends, Forecasts [2032][1]
  2. Servier: Full Year 2021/22 Results Confirm the Transformation Trajectory of the Group[2]
  3. Valuates Reports: Global and India Oncaspar Market Report & Forecast 2023-2029[3]
  4. Business Research Insights: Oncaspar Market Size, Share, & Industry Growth [2032][4]
  5. Servier: Servier Confirms its 2025 Trajectory to Achieve its 2030 Ambition[5]

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.